Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study

• Published in: Journal of psychopharmacology (Oxford) Vol. 32; no. 5; pp. 524 - 532
• Main Authors: Zhou, Yanling, Li, Guannan, Li, Dan, Cui, Hongmei, Ning, Yuping
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-05-2018; Sage Publications Ltd
• Subjects: Antipsychotics; Cognitive ability; Drug therapy; Emotional behavior; Extrapyramidal system; Long-term effects; Memory; Mental disorders; Olanzapine; Patients; Psychotropic drugs; Risperidone; Schizophrenia; Short term memory; Side effects; Vigilance; dose reduction; antipsychotics; symptomatology; schizophrenia; Cognitive function
• ISSN: 0269-8811; 1461-7285
• DOI: 10.1177/0269881118756062

Background:
The long-term effects of dose reduction of atypical antipsychotics on cognitive function and symptomatology in stable patients with schizophrenia remain unclear. We sought to determine the change in cognitive function and symptomatology after reducing risperidone or olanzapine dosage in stable schizophrenic patients.
Methods:
Seventy-five stabilized schizophrenic patients prescribed risperidone (≥4 mg/day) or olanzapine (≥10 mg/day) were randomly divided into a dose-reduction group (n=37) and a maintenance group (n=38). For the dose-reduction group, the dose of antipsychotics was reduced by 50%; for the maintenance group, the dose remained unchanged throughout the whole study. The Positive and Negative Syndrome Scale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects, and Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery were measured at baseline, 12, 28, and 52 weeks. Linear mixed models were performed to compare the Positive and Negative Syndrome Scale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects and MATRICS Consensus Cognitive Battery scores between groups.
Results:
The linear mixed model showed significant time by group interactions on the Positive and Negative Syndrome Scale negative symptoms, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects, speed of processing, attention/vigilance, working memory and total score of MATRICS Consensus Cognitive Battery (all p<0.05). Post hoc analyses showed significant improvement in Positive and Negative Syndrome Scale negative subscale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects, speed of processing, working memory and total score of MATRICS Consensus Cognitive Battery for the dose reduction group compared with those for the maintenance group (all p<0.05).
Conclusions:
This study indicated that a risperidone or olanzapine dose reduction of 50% may not lead to more severe symptomatology but can improve speed of processing, working memory and negative symptoms in patients with stabilized schizophrenia.